Heska’s (HSKA) “Buy” Rating Reiterated at Raymond James Financial

Raymond James Financial restated their buy rating on shares of Heska (NASDAQ:HSKA) in a research report released on Monday.

A number of other equities analysts have also commented on the company. B. Riley reiterated a hold rating and issued a $96.50 price objective on shares of Heska in a research note on Friday, October 27th. Canaccord Genuity initiated coverage on Heska in a research note on Thursday, October 5th. They issued a buy rating and a $115.00 price objective on the stock. BidaskClub lowered Heska from a buy rating to a hold rating in a research note on Monday, August 14th. Zacks Investment Research lowered Heska from a buy rating to a hold rating in a research note on Wednesday, October 4th. Finally, Benchmark reiterated a buy rating and issued a $120.00 price objective (up from $106.00) on shares of Heska in a research note on Wednesday, August 9th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $113.30.

Heska (HSKA) opened at $81.98 on Monday. The company has a market capitalization of $615.29, a PE ratio of 44.47, a PEG ratio of 2.27 and a beta of 0.75. Heska has a 12 month low of $66.51 and a 12 month high of $115.00.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $31.40 million for the quarter, compared to analyst estimates of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The firm’s revenue for the quarter was down 6.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.45 earnings per share. equities analysts expect that Heska will post 2.03 EPS for the current fiscal year.

In related news, insider Michael J. Mcginley sold 7,826 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares in the company, valued at $9,304,024.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 14.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of HSKA. Royal Bank of Canada increased its stake in Heska by 96.9% during the second quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after acquiring an additional 499 shares during the period. SG Americas Securities LLC bought a new stake in shares of Heska in the 3rd quarter valued at approximately $108,000. Victory Capital Management Inc. grew its stake in shares of Heska by 17.5% in the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 169 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of Heska in the 2nd quarter valued at approximately $127,000. Finally, LS Investment Advisors LLC grew its stake in shares of Heska by 411.2% in the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 1,028 shares during the period. Hedge funds and other institutional investors own 81.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thestockobserver.com/2017/12/08/heskas-hska-buy-rating-reiterated-at-raymond-james-financial.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply